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ABSTRACT 
 
This study investigated whether regular aerobic exercise training could prevent the 
dysregulation of autonomic cardiovascular (CV) control in a streptozotocin (STZ)-
diabetes model designed to represent clinical type 1 diabetes mellitus (T1DM). Rats were 
divided into control (C), control exercise (CX), diabetic (D) and diabetic exercise (DX) 
groups. Baroreflex sensitivity (BRS), heart rate variability (HRV) and vascular 
sympathetic tone (VST) were measured following 10 weeks of exercise. 
Parasympathetic-mediated bradycardia BRS was reduced in D compared to C and DX 
(p<0.05). The HF (parasympathetic) HRV was reduced in D compared to CX and DX 
(p<0.05) and the LF/HF ratio (sympathetic HRV) was elevated in D compared to all other 
groups (p<0.05). The VST was increased in D compared to all other groups (p<0.05). 
Diabetes caused a CV autonomic imbalance, which was prevented by exercise training. 
Thus, this model paralleled clinical T1DM and demonstrated that exercise can prevent 
autonomic dysfunction. 
 
 
 
 
 
Keywords: type 1 diabetes, aerobic exercise, diabetic autonomic neuropathy, 
cardiovascular autonomic neuropathy, sympathetic overactivity, heart rate variability, 
baroreflex sensitivity, parasympathetic nervous system 
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CHAPTER 1 
1.1 Introduction 
Type 1 diabetes mellitus (T1DM) is an idiopathic autoimmune disease that 
results in the destruction of pancreatic β cells and subsequently, the inability to 
produce endogenous insulin (4, 7, 144). This results in chronic hyperglycemia and 
imbalances of fat, protein, and carbohydrate metabolism that lead to progressive 
complications, such  as: retinopathy, nephropathy, neuropathy and increased risk of 
microvascular and macrovascular disease (4, 7, 24). These complications can be so 
severe that, even with insulin therapy, a child diagnosed with diabetes at 10 years of 
age will lose an average of 19 years of life due to the disease (97). Epidemiological 
studies have shown that T1DM incidence is continuously rising in both high and low 
incidence populations; particularly, in the 15 years of age and younger demographic 
(63, 99, 163). For example, Onkamo et al. (99) reported that the global incidence rate 
of the under 15 demographic from 1960 to 1996 increased at 3% per year. The 
DiaMond Project Group (26), a multinational effort to investigate and monitor the 
incidence patterns of childhood type 1 diabetes, reported a yearly global increase in 
incidence of 3.4% for the years 1995 to 1999. In Europe it has been predicted that by 
2020 the number of children under the age of 5 afflicted with T1DM will double and 
the number of cases for children under the age of 15 will increase by 70% (104). 
Clearly, this demonstrates that T1DM is a problem that is continuously growing in 
prevalence and importance. Also of importance are the financial costs of T1DM on 
patients and society at large (130). In fact, it was found that patient costs for 
individuals with T1DM are disproportionately higher than costs for those with type 2 
diabetes mellitus (T2DM) (142). Furthermore, the societal costs of T1DM in the USA 
and the UK are estimated at $14.4 billion and $3 billion per year, respectively (46, 
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142). In light of such profound health and economic impacts, understanding the 
predictors, onset and treatment of T1DM has been a focus of extensive investigation; 
yet, a substantial amount about the disease and its complications remains to be 
elucidated. Although it has been long understood that exercise can generate beneficial 
health outcomes, more recently and increasingly, exercise is being regarded as a 
therapy and is being prescribed by physicians as medicine (123, 128). The benefits of 
exercise in the prevention and treatment of T1DM-related complications has been 
well documented (36, 105, 112). In particular, diabetic autonomic neuropathy (DAN) 
is known to be one of the earliest complications of diabetes which not only precludes 
a variety of related complications but is also directly linked to increased mortality  
(30, 40, 100, 149). Thus, the ability of exercise therapy to reduce DAN is a research 
focus of great importance (9, 18, 105, 150). This chapter will provide an overview of 
T1DM onset and its mediation of neuropathy, the function of the autonomic nervous 
system and its regulation of the cardiovascular system, how neuropathy leads to 
autonomic and cardiovascular dysfunction and the efficacy of exercise in mitigating 
this dysfunction.  
 
1.2 Etiology of Type 1 Diabetes Mellitus 
 Susceptibility to T1DM is determined by both genetic and environmental 
factors (7, 31, 58, 144). The genetic basis of the disease is strongly exhibited by 
studies of monozygotic and dizygotic twins. It has been found that monozygotic twins 
can demonstrate over a 50% concordance rate of T1DM, which is far greater than the 
concordance between dizygotic twins (50). Due to the fact that monozygotic twins 
share the same DNA and developmental environment, whereas dizygotic twins have 
non-identical DNA but also share the same developmental environment, it can be 
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concluded that the difference in concordance between the two types of twins is 
resultant of a genetic influence (31). Through such twin studies, as well as familial 
linkage studies, it has been established that the human leukocyte antigen (HLA) 
encoding genes, which code for many different components of the immune system, 
are the major factors conferring genetic susceptibility to T1DM (24, 31, 48, 50). 
Although a high percentage of T1DM susceptibility can be attributed to a genetic 
component, even at 50% concordance, there remain at least equally substantial non-
genetic factors that are involved in the manifestation of T1DM.  
Environmental factors, including viral infections, diet, growth, toxins and 
stress, have been implicated in the pathogenesis of T1DM (3). D’Angeli et al. (28) 
provide evidence for the “hygiene hypothesis” by demonstrating that a clean 
environment during childhood decreases antigenic stimulation and results in a greater 
vulnerability to developing T1DM.  Further evidence of an environmental 
determinant of T1DM is the apparent role of geography and climate in its prevalence. 
In both Europe and North America there is a north to south, high to low, gradient of 
incidence (58, 144). In accordance with a climatic influence, a lower incidence of 
T1DM during warm seasons than cold seasons has been observed within populations 
(58, 68). Although these genetic, regional and climatic insights provide evidence of 
risk factors for developing T1DM, they are not necessarily predictors of great utility. 
The environmental factors may be correlated with T1DM but most cannot realistically 
be avoided or managed, whereas the genetic factors alone do not yield disease onset; 
as evidenced by the finding that, at most, only 10% of individuals with the highest 
risk susceptibility genes actually become afflicted with T1DM (146).  
The most effective predictors of T1DM are a complement of autoantibodies 
that can be detected years before the disease develops; in fact, they can even be 
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detected during infancy (12, 61). The autoantibodies that predict T1DM are: islet cell 
antibodies (ICA), insulin autoantibodies (IAA), glutamic acid decarboxylase 
antibodies (GADA) and protein tyrosine phosphatase-2 antibodies (IA-2A) (71, 80). 
These autoantibodies direct the infiltration of immune cells, mostly T cells, to the 
islets and facilitate their inflammation and the destruction of β cells (19, 25, 71). It 
has been observed that the detection of two or more of these autoantibodies in 
relatives of T1DM patients has a 90% predictive value for their eventual development 
of T1DM (147). In the general population, marginally elevated levels of 3 to 4 
autoantibodies indicates a risk of roughly 60% for the development of T1DM (12). 
Despite the predictive value of autoantibody detection, no autoantibody based 
treatments exist to avert the onset of T1DM (25). Therefore, for now, the only way to 
delay or prevent T1DM associated morbidity and mortality is to understand and 
ameliorate the progression of the disease-related complications (4, 25, 80). However, 
it has been suggested that exercise could ameliorate the severity of autoantibody 
mediated inflammation and subsequently, reduce T1DM initiation and progression 
(66).  
 
1.3 Pathogenesis of Neuropathy in T1DM 
The neurological complications of T1DM are understood to arise from either a 
metabolic etiology, a vascular etiology or a combination of both (30, 41, 137, 156). 
However, the pathology of metabolism and vasculature in T1DM, as well as the wider 
breadth of complications that develop, arises primarily due to chronic hyperglycemia 
(24, 41, 149). Indeed, the duration and severity of hyperglycemia have both been 
indicated as predictors of the degree of diabetic neuropathy (30, 41). Fittingly then, 
advanced glycation end-products (AGEs), which are formed when hyperglycemia 
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leads to irreversible binding of glucose molecules to intracellular and extracellular 
proteins, have been implicated as a causative link between vascular and metabolic 
dysfunction in T1DM (41).  
 The metabolic factors, whose dysfunction primarily contributes to diabetic 
neuropathy, are many. For example, T1DM leads to increased polyol pathway activity 
and decreased myo-inositol, which are associated with decreased nerve conduction 
velocity (30, 41, 137). It also causes decreased nerve Na/K ATPase activity, the 
function of which is necessary to maintain the transmembrane ionic gradient required 
for electrical impulse conduction (41, 137). Further, T1DM is associated with 
decreased synthesis and transport of axonal proteins, which are supplied from the cell 
body to maintain structural and functional integrity of the axon (41, 87, 137) and 
diminished incorporation of glycolipids and amino acids into myelin, thereby 
reducing axon insulation and conduction velocity (30, 41, 139). T1DM also leads to 
decreased nerve protein kinase C (PKC) activity, which can further reduce Na/K 
ATPase activity (137). Dyslipidemia, consisting of increased triglycerides, increased 
low-density lipoprotein and decreased high-density lipoprotein, is a metabolic factor 
that contributes to neuropathy via the atherosclerotic impairment of the vasculature 
(30, 41, 107).  
Vascular factors that contribute to diabetic neuropathy mostly involve 
pathology of the endoneurial capillaries (92, 152). These vascular impairments 
include: basement membrane thickening and endothelial cell swelling and 
proliferation, resulting in reduced luminal diameter,  decreased nerve blood flow and 
endoneurial hypoxia (41, 83, 143); degeneration of pericytes, which are integral for 
maintaining endothelial cell function at the blood-nerve barrier (41, 129); and 
ultimately, endoneurial capillary atherosclerosis, which leads to the dysregulation of 
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nutrient exchange between axons and blood vessels across the endoneurium  (30, 41, 
129, 143). There is also evidence that hyperglycemia can have tissue-specific, 
bidirectional effects on PKC activity (138). While hyperglycemia decreases PKC 
activity in the nerve as mentioned above, it also becomes overactive in vascular 
endothelium and leads to increased endothelial permeability, the dysregulation of 
endothelial-derived vasodilator nitric oxide (NO) and thus, diminished blood flow 
(127, 138).   
 Despite these metabolic and vascular factors often being considered discrete 
etiologies of diabetic neuropathy, it is more likely that they arise concomitantly and 
share protein glycation as their common cause (see Figure 1.1) (30, 41). For example, 
glycation of antioxidant enzymes hinders their ability to remove reactive oxygen 
species (ROS). This results in the accumulation of ROS that damage membranes, 
cellular proteins and DNA, all of which contribute to neuropathic progression (41). 
Glycation of the nitric oxide synthase (NOS) enzyme  is likely a mechanism by which 
NO production is decreased, driving  the vascular dysfunction described above (41, 
138). Also, glycated elastin and collagen in the endothelium can restrict access of NO 
to the smooth muscle, further inhibiting NO-mediated vasodilation, reducing nerve 
blood flow and nerve oxygenation (41). The manifestation of AGEs in the basement 
membrane, elastic lamina and endothelial cells of the blood vessels causes 
macrophage infiltration, which release macrophage-derived growth factors , leading 
to smooth muscle proliferation and atherogenesis (41). Due to evidence that 
inflammatory cytokines also cause vascular damage by inducing excessive ROS, it is 
plausible that AGE-mediated inflammation is the primary cause of neurovascular 
dysfunction in diabetic neuropathy (36, 134). AGE levels in the endoneurium and 
associated microvessels have been observed to correlate with the degree of axonal 
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atrophy in nerve biopsies; with AGE immunoreactivity detected in 90% of peripheral 
nerves of diabetics compared to a complete absence of AGEs in controls (91). 
Whether or not AGEs can be said to underlay both the metabolic and vascular causes 
of neuropathy, they certainly do represent a link between them. Ultimately, 
hyperglycemia-mediated AGEs, metabolic dysregulation and vascular dysfunction are 
all fundamental to nerve dysfunction and degeneration in T1DM. 
 
1.4 The Autonomic Nervous System and Mechanisms of Autonomic Cardiovascular 
Regulation 
The autonomic nervous system (ANS) is a network of efferent and afferent 
nerves linked to structures of the central nervous system (CNS) that, together, govern 
the motor control of visceral organs (40, 76). Since targets of the ANS include 
multiple endocrine organs, the cardiovascular (CV) system and regions of CNS, the 
ANS is a powerful regulator of homeostasis throughout the entire body (76, 124). The 
ANS differentially regulates these systems by using two antagonistic branches, the 
sympathetic nervous system (SNS) and the parasympathetic nervous system (PSNS), 
which mutually inhibit one another (116). The main neurochemical difference 
between the SNS and PSNS is the neurotransmitters involved in signaling to the target 
organs. Preganglionic neurons of both branches utilize acetylcholine as their primary 
neurotransmitter, whereas the postganglionic neurons of the PSNS emit primarily 
acetylcholine and the postganglionic neurons of the SNS release primarily 
norepinephrine (76, 116). The use of these different neurotransmitters underlies the 
antagonistic physiological actions of the two branches of the ANS (76, 116). To 
understand the discrete roles of the SNS and PSNS in controlling bodily functions, the 
mnemonics “fight or flight” and “rest and digest” are used, respectively (116, 149). 
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The SNS directs oxygen and energy toward organ systems that are recruited in 
stressful or active situations; for example, it acts to increase heart rate (HR) and 
decrease enteric motility. The PSNS, on the other hand, promotes conservation and 
restoration of energy and so, stimulates functions that are more useful at rest while 
inhibiting others; for example, it decreases blood pressure (BP) and facilitates the 
excretion of waste (76, 116). When functioning properly, these two branches maintain 
chronic homeostasis of visceral organ function (116). 
One such autonomically-mediated mechanism of homeostasis is the regulation 
of CV function by the baroreflex (see Figure 1.2). Afferent arterial baroreceptors are 
stretch-sensitive mechanoreceptors located in the aortic arch, carotid sinus and 
elsewhere in the vasculature that send frequency coded signals to the brainstem in 
order to signal increases and decreases in BP (40). Once these signals arrive at the 
brainstem they are processed by several structures that govern the efferent 
sympathetic and parasympathetic output to the heart, the vasculature, kidneys and 
other visceral organs (40, 116). The four major brain regions involved in processing 
these signals include the hypothalamus and three regions of the brainstem: the rostral 
ventrolateral medulla (RVLM), the caudal ventrolateral medulla (CVLM) and the 
nucleus of the solitary tract (NTS) (40, 76, 116). When a rise in BP above the set 
physiological range occurs, the baroreceptors fire rapidly and stimulate the NTS. The 
NTS in turn stimulates the CVLM, which provides inhibitory input to the RVLM. 
Since the RVLM has excitatory input to sympathetic preganglionic neurons in the 
intermediolateral (IML) column of the thoraco-lumbar spinal cord, when 
baroreceptors fire the RVLM, and by extension sympathetic outflow, is inhibited and 
the autonomic balance shifts towards greater parasympathetic activity; the outcome of 
which is reduced HR and the restoration of BP to the physiological range (8, 40, 116). 
9 
 
Alternatively, when arterial pressure declines below the set physiological range, 
baroreceptor firing decreases, removing the stimulation of the NTS and CVLM and 
disinhibiting the RVLM, resulting in increased sympathetic outflow, HR and again, 
the restoration of BP to the physiological range (40, 116).  
The baroreflex also has an important influence on total peripheral resistance 
(TPR); which is the resistance of all peripheral vasculature in the systemic circulation 
(145). Peripheral resistance and the variables that influence it can be described by 
Poiseuille’s law, 𝑅 =  𝛥𝑃
𝑄
 ; where R is resistance, ΔP is the change in pressure between 
two points and Q is the blood flow, which is equivalent to cardiac output (90). 
Resistance can also be represented as 𝑅 = 8ɳ𝐿
𝜋r4
; where ɳ is the viscosity of the fluid, L 
is the length of the vessel, and r is the radius (90). Blood pressure and blood flow 
(cardiac output) are acutely regulated by the baroreflex (77). However, beat-to-beat 
changes in TPR are difficult to measure and thus, most studies examine feedback 
control of HR as opposed to TPR when assessing the baroreflex (10). 
The paraventricular nucleus (PVN) of the hypothalamus also modulates 
sympathetic outflow (11, 21, 40). The PVN receives inputs from circulating hormones 
and molecules (such as norepinephrine and glucose), visceral receptors that detect 
osmolarity and blood volume and other regions of the brain (11). The PVN has many 
complex effector subnuclei but its effects can be summed through its three major 
connections. The magnocellular neurons of the PVN are large cells that interact with 
the posterior pituitary to release oxytocin and vasopressin (also known as antidiuretic 
hormone, ADH; a vasoconstrictor and mediator of water absorption in the kidneys) 
into the blood (113). The medial parvocellular neurons synthesize corticotropin 
releasing hormone (CRH), which stimulates the release of adrenocorticotropic 
hormone (ACTH) from the anterior pituitary, which then acts on the adrenal cortex to 
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stimulate aldosterone (a mediator of water retention in the kidneys)and cortisol 
production (which stimulates gluconeogenesis in the liver); this constitutes what is 
known as the hypothalamo-pituitary-adrenocortical (HPA) axis (11, 125). Another 
subset of parvocellular PVN neurons have direct connections to the RVLM in the 
brainstem and the IML in the spinal cord (8). Thus, these PVN neurons can directly 
and indirectly influence sympathetic nerve activity via inputs to preganglionic 
sympathetic neurons and by modulating RVLM activity (8). Indeed, it has been 
demonstrated that sympathoexcitation is elicited through the PVN in response to a 
drop in blood volume, without a drop in pressure, via the activation of both RVLM 
and ILM connected neurons (8). Conversely,  the autonomic neurons of the PVN have 
been reported to selectively decrease renal sympathetic activity and increase cardiac 
sympathetic activity in response to blood volume expansion (21).  This demonstrates 
that the PVN’s influence on BP and the CV system is mediated through hormones, 
sympathetic neurons and interactions with the kidney. The stimulation of sympathetic 
activity by PVN neurons in response to increased circulating angiotensin II (ANG II), 
generated by the renin-angiotensin-aldosterone system (RAAS), is another example of 
its interaction with the kidneys (11, 54). 
Renin release from juxtaglomerular cells of the kidney primarily occurs in 
response to hypovolemia and increased osmolarity but can also be produced by 
sympathetic stimulation (11, 20, 38). Once released, the renin enzyme acts locally and 
systemically in the blood to cleave angiotensinogen, which is constitutively secreted 
by the liver into circulation, to form angiotensin I (38).  Angiotensin I is then cleaved 
by angiotensin-converting-enzyme (ACE), which is found in blood plasma, vascular 
endothelial cells, the kidneys, the brain, the lungs and many other tissues  (38, 40). 
The product of ACE cleavage is the biologically active ANG II which has a multitude 
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of effects on numerous organs and tissues. For instance, ANG II is a potent 
vasoconstrictor, it acts on presynaptic receptors of sympathetic nerve terminals to 
potentiate norepinephrine release, it decreases glomerular filtration rate and increases 
reabsorption of sodium and water into the blood and it stimulates aldosterone release 
from the adrenal cortex, thus completing the RAAS (38). It also acts on the 
subfornical organ (a circumventricular organ of the brain) to stimulate PVN mediated 
sympathoexcitation to the heart and kidneys (20, 40, 54). However, it is very 
important to note that this classic, endocrine view of the RAAS has undergone 
profound conceptual change due to the discovery of local, tissue-intrinsic renin-
angiotensin systems (RAS – note the distinct acronyms denoting local and circulatory 
renin-angiotensin systems) and its importance in autocrine and paracrine signalling 
which act independently of the circulating RAAS factors (32, 115). 
Thus, both neural and humoral mechanisms interact with the ANS to modulate 
autonomic activity and CV function. For example, the PVN and the RAAS influence 
blood volume, vascular tone and BP; baroreceptors regulate BP and maintain it within 
a set range by modulating cardiac function; ANG II produced by the RAAS can act 
directly on peripheral sympathetic synapses and can modulate PVN activity; and the 
PVN can directly modulate sympathetic outflow and influence the brainstem circuitry 
that mediates the baroreflex (40). All of these systems are integrated through the ANS 
and cooperate to maintain CV homeostasis.  
 
1.5 Autonomic Dysfunction and Cardiovascular Dysregulation in T1DM 
Dysfunction of the ANS is a common and serious complication of T1DM that 
can result in dysregulation of all of the organ systems under its control (30). Known 
as diabetic autonomic neuropathy (DAN), prevalence of this condition has been 
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reported to vary widely, ranging from roughly 10-90% in diabetics depending on the 
assessment criteria used (30, 149). The clinical manifestations of DAN are also 
variable due to the systemic influence of the ANS and can include orthostatic 
hypotension, tachycardia, hypertension, silent myocardial ischemia, gastroparesis, 
xerostomia, decreased heart rate variability (HRV), anhidrosis and many others 
symptoms (30, 33, 69, 95, 149). However, it should be noted that experimental forms 
of diabetes do not always faithfully replicate the full spectrum of clinical 
complications; in some cases, opposing outcomes have been observed, such as resting 
bradycardia and hypotension (6, 47, 81). However, unlike the clinical population, 
most of these studies do not use insulin therapy to manage hyperglycemia, which has 
been shown to reverse those effects (47). DAN can also be a considerably deadly 
complication of T1DM as it underlies diabetes-mediated CV dysfunction (85, 100). 
Indeed, based on an analysis of the Pittsburgh Epidemiology of Diabetes 
Complications Study, Orchard et al. (100) found that mortality increased fourfold in 
patients with DAN.  Similarly, a meta-analysis by Maser et al. (85) found that 
cardiovascular autonomic neuropathy (CAN), a subset of DAN, significantly 
increased the relative risk of mortality by a factor of 3.45. Another form of mortality 
in T1DM is the occurrence of sudden nocturnal death (100, 154). This so called “dead 
in bed” syndrome is thought to be exacerbated by increased susceptibility to nocturnal 
hypoglycemia resulting from abnormal pancreatic α-cell function and impaired 
glucagon release (140, 154). However, even this impaired glucagon response is 
thought to be mediated by autonomic dysfunction and furthermore, sudden death in 
T1DM is more greatly attributed to cardiac arrhythmia than hypoglycemia; thus, 
“dead in bed” syndrome is likely resultant of DAN (140, 154). DAN, therefore, has a 
significant impact on the quality of life, morbidity and mortality of patients with 
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T1DM; the most deadly consequences of which are mediated by loss of CV control 
via CAN (30, 101, 149, 151). 
As described previously, the etiology of general diabetic neuropathy and thus, 
DAN, in T1DM is linked to chronic hyperglycemia (127, 155). Evidence of this was 
reported by the Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group (98) who 
observed that maintenance of near normoglycemia via intensive insulin therapy 
reduced neurologic complications of T1DM and resulted in a 42% decrease in the risk 
of any CV disease event, such as myocardial infarction, stroke or death. The 
neuropathic effects of hyperglycemia that mediate DAN usually affect longer nerves 
first and since the single longest ANS nerve, the vagus nerve, facilitates 75% of all 
parasympathetic activity, a sympathovagal imbalance leading to sympathetic 
overactivity is purported to be an early cause of CAN (30, 149, 151). Furthermore, 
hyperglycemia can lead directly and indirectly to increased sympathetic outflow, 
indicating peripheral and central mechanisms are behind ANS and CV dysfunction in 
T1DM (108, 148). It is pertinent then to understand how the regulation of autonomic 
activity and CV function are affected by T1DM. 
Although there has been some evidence for increased RAAS activity in T1DM 
and hyperglycemia, most of the literature has demonstrated that systemic components 
of the RAAS, such as plasma renin, aldosterone and ANG II, are suppressed (13, 22, 
73, 89). When considering this in the context of the physiological action of circulating 
ANG II (vasoconstriction, volume expansion and sympathoexcitation), it should 
follow that it is not involved in the increased BP and sympathetic tone observed in 
T1DM; however, this is not the case (115, 148). More recent evidence implicates the 
role of local, tissue-intrinsic RAS systems in the pathology of diabetes-related 
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complications (109, 115). Hyperglycemia has been shown to increase local RAS 
activity in numerous tissues and this process is being connected to the onset of many 
downstream complications of T1DM; including, nephropathy, retinopathy and cardiac 
myopathy (27, 34, 67, 110). This widespread deleterious effect of local RAS 
overactivity in diabetes is likely interconnected to oxidative damage mediated by 
locally produced ANG II (34, 115). Thus, RAS activation in diabetes is believed to 
contribute to microvascular complications and has a probable role in the vascular 
etiology of neuropathy (86, 109). Due to the presence of RAS in the brain and the 
known ability of ANG II in the subfornical organ to elicit PVN-mediated increases in 
sympathetic activity, there exists a plausible mechanism by which local RAS may be 
driving increased sympathetic outflow in T1DM (11, 148).  
The PVN of the hypothalamus is known to influence the basal level of 
sympathetic outflow (60). In T1DM there are increases in both basal PVN activity and 
sympathetic activity (35, 56). It has been demonstrated that the excitation of the PVN 
by ANG II is enhanced in rats with streptozotocin (STZ)-induced diabetes; an 
experimental form of T1DM produced by STZ-mediated destruction of β-cells (103). 
This suggests that diabetes induced elevations of sympathetic outflow could be due to 
increased levels of ANG II in the brain produced by local RAS system activation or 
increased sensitivity to ANG II in the PVN (103). Another previously described 
diabetes-related deficit that is also a mechanism contributing to central sympathetic 
overactivity in T1DM is the loss of NOS activity and NO (138, 161). NO is a known 
inhibitor of PVN activity that acts by increasing GABAergic input to the PVN (160). 
Zheng et al. (161) found that STZ-diabetic rats had fewer neuronal NOS (nNOS) 
positive cells and lower NO release in the PVN compared to controls. Thus, there is a 
reduction of GABA inhibition on the PVN in T1DM that facilitates its overactivity 
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and thereby, contributes to sympathetic  overactivity (114). Furthermore, 
overstimulation of the PVN would also cause excitation of magnocellular neurons, 
resulting in the release of vasopressin, which would contribute to increased BP via 
direct vasoconstriction and volume expansion (70). However, the aberration of 
sympathetic tone in diabetes is more directly influenced by the parvocellular neurons 
of the PVN due to their association with the RVLM and IML; hence, PVN 
dysfunction can dysregulate sympathetic outflow and CV parameters by modulating 
neural control of HR, BP and the baroreflex (20, 60, 103).  
The baroreflex itself is an important regulator of sympathetic and 
parasympathetic outflow, BP, HR and TPR (84). Baroreflex dysfunction, in both 
sensitivity and set point, is an established consequence of T1DM, with reductions in 
sensitivity observed to occur as early as 5 days after STZ-diabetes induction (15, 23, 
81). Thus, studies have investigated how each aspect of the baroreflex arc are 
uniquely affected in T1DM; this arc consists of baroreceptors, baroreceptor afferents, 
central regulators and sympathetic and parasympathetic efferents (74). Salgado et al. 
(122) found that aortic baroreceptor neurons have reduced activity in STZ-diabetic 
rats. Further, they determined that the aortic depressor nerves, the afferent nerves 
between baroreceptor neurons and the brainstem, showed morphological signs of 
axonal atrophy by measuring the G ratio; the ratio between axon diameter and whole 
fiber diameter (122). Li et al. (72) observed that the excitability of aortic 
baroreceptors, which mediates the set point of baroreceptor firing, was blunted in 
STZ-diabetic rats and that later, this reduced excitability was due to up-regulated, 
ANG II-NADPH oxidase derived, superoxide within the baroreceptor ganglion (73). 
They also found that microinjection of an ANG II receptor antagonist into the nodose 
ganglia restored aortic baroreceptor excitability, making the case for diabetes-induced 
16 
 
local RAS activity being responsible for dysfunction of the afferent portion of the 
baroreflex arc (73). Evidence for the dysfunction of central regulation of the 
baroreflex was presented by Gu et al. (39) using OVE26 T1DM mice; a transgenic 
model of T1DM that acquires β-cell damage through an overexpressed calmodulin 
regulated by an insulin promoter. They found that these mice, compared to controls, 
had a less prominent bradycardia response to aortic depressor nerve stimulation but 
that the bradycardia response to vagal efferent stimulation was increased; suggesting a 
central mechanism was responsible for the blunted response to baroreceptor 
stimulation (39). Also, Chen et al. (16) documented a reduced firing rate in the NTS, 
both basally and after phenylephrine injection, in STZ-induced diabetic rats compared 
to controls. This decreased activity was implicated in their observation of decreased 
baroreflex sensitivity (BRS) and could possibly indicate chronic disinhibition of the 
RVLM; and therefore, increased sympathetic outflow (16). Of the two efferent arms 
of the ANS, the PSNS appears to be the one primarily impaired in T1DM. Maeda et 
al. (81) reported significant decreases in both basal PSNS tone and responsiveness to 
hypertensive drugs in STZ-induced diabetic rats; but non-significant changes to 
similar parameters in the SNS. Lund et al. (79) found that choline acetyltransferase 
(ChAT, the enzyme that produces the chief neurotransmitter of the PSNS, 
acetylcholine), had reduced activity in the hearts of diabetic rats as early as 4 weeks 
post-STZ induction. After 8 weeks of diabetes, they measured a reduction in cardiac 
ganglion size and number, prompting the conclusion that these PSNS deficits may 
contribute to the impaired parasympathetic control of the heart, sympathetic 
overactivity and baroreflex blunting that is common in T1DM (79).  
A non-invasive functional measure capable of detecting such impaired 
autonomic control of the heart in T1DM is the assessment of HRV (75). HRV can be 
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measured by time domain analyses, measuring the changes in the standard deviation 
between R-R intervals or by frequency domain analyses, using Fourier analysis to 
disintegrate HR variance into underlying high and low frequencies (136). Regardless 
of which method is chosen, HRV has been described as one of the earliest indicators 
of autonomic dysfunction in T1DM (126, 162). A variable HR has been known to be 
a characteristic of a healthy heart for roughly a century (37). In frequency domain 
analysis, high frequency (HF) variation (0.15-.4Hz) is considered to be mediated by 
parasympathetic activity, whereas low frequency (LF) variation (0.04-0.15Hz) is 
considered to be entrained by the oscillation of baroreceptor firing; and so, it is 
modulated by both parasympathetic and sympathetic activity (37, 136). As described 
above, T1DM results in baroreflex dysfunction that is largely attributed to damage of 
the PSNS (29). Since PSNS dysfunction occurs first, a reduction in HF variability is 
usually the first sign of autonomic dysfunction (52). Thus, in general, a reduction in 
HRV in T1DM is associated with the onset of autonomic dysfunction and more 
specifically, the loss of parasympathetic tone and baroreflex dysfunction (37, 126, 
157). Now used as a standard indicator in the diagnosis of cardiac autonomic 
neuropathy, reduced HRV is associated with cardiac arrhythmias that can have mortal 
consequences for diabetics and is therefore an important marker of autonomic 
function in T1DM (151).  
 
1.6 The Effects of Exercise on Neuropathy, Autonomic Regulation and 
Cardiovascular Dysregulation in T1DM  
Exercise training is a well-established and widely prescribed non-
pharmacological therapy capable of ameliorating a wide breadth of diseases and their 
complications (98, 105, 141). For example, exercise has been demonstrated to 
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improve heart disease, pulmonary disease, muscle disease, bone disease, joint disease, 
cancer, depression, asthma, obesity, hypertension, dyslipidemia, insulin resistance, 
type 2 and type 1 diabetes (18, 105, 123, 128). Beyond just treating disease, exercise 
is also associated with preventing disease risk factors and manifestation. It has been 
shown to improve cognitive performance, increase longevity and has a strong 
negative correlation with all-cause mortality (1, 64, 78). One of the underlying 
principles likely facilitating the benefits of exercise is the concept of “hormesis”; 
wherein low level stress or damage causes a disruption of homeostasis and results in 
an adaptive overcompensation and increased fitness of a physiological system (14, 
36). In the case of exercise, the acute induction of low-level oxidative stress and 
inflammation results in an increase of endogenous antioxidant enzymes and anti-
inflammatory mediators (59, 132). Continuous exercise training results in the chronic 
upregulation of antioxidants and anti-inflammatory agents which confers constitutive 
resistance to other sources of pathogenic insult (132, 133). Another outcome of 
exercise, which is especially important in diabetes, is increased insulin sensitivity and 
glucose tolerance (43). Exercise training increases the amount and function of 
proteins in the insulin signalling cascade, which facilitates the translocation of glucose 
transporter 4 (GLUT4) into the skeletal muscle membrane (53). Furthermore, muscle 
contraction can upregulate GLUT4 translocation to the plasma membrane via an 
insulin-independent mechanism (118). In T1DM, hyperglycemia mediated ROS act to 
decrease insulin sensitivity by impairing the insulin cascade and GLUT4 translocation 
(44). Therefore, the antioxidant, anti-inflammatory and glucoregulatory effects of 
exercise make it a potent therapy for T1DM and many of its complications (9, 36). 
 The influence of exercise on insulin sensitivity and glucose tolerance both 
directly and indirectly affects nerve health. This is because neither nerves nor 
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endoneurium express GLUT4 or utilize it to transport glucose; instead, they use 
GLUT1 and GLUT3 which do not require insulin for translocation and are 
constitutively active (82, 131). Thus, exercise-mediated sensitization to insulin does 
not occur within neural tissue, yet through improving glucose tolerance in other 
tissues, exercise reduces exogenous insulin requirements and neural hyperglycemic 
insult in T1DM (105, 112, 158). This moderated hyperglycemia reduces the level of 
AGEs, which are known to be major contributors to neuropathy through ROS 
formation and inflammation in the neurovasculature (36, 41, 117). Furthermore, 
exercise-induced insulin sensitivity and AGE reduction also means increased NO 
production and bioavailability, resulting in enhanced function of endoneurial 
capillaries and oxygen delivery to peripheral nerves (117, 135, 138). Exercise training 
also increases endothelial Cu/Zn-superoxide dismutase (SOD) and mitochondrial Mn-
SOD antioxidant enzymes independently of hyperglycemic status, while 
simultaneously decreasing inflammatory cytokines and increasing anti-inflammatory 
mediators (51, 59, 93). Thus, exercise training is capable of ameliorating neuropathy 
through the alleviation of both its metabolic and vascular etiologies by improving 
glucose metabolism and upregulating antioxidant and anti-inflammatory mediators 
(36, 112, 158). Indeed, exercise training has been shown to both, prevent diabetic 
neuropathy from occurring and improve nerve function in individuals previously 
diagnosed with diabetic neuropathy (9, 62).  
 Another mediator of T1DM complications that is influenced by exercise is the 
local RAS (115, 121). RAS overactivity has been shown to be mediated by 
hyperglycemia and is implicated in causing insulin resistance (45, 148). As previously 
described, exercise can reduce hyperglycemia and so can decrease hyperglycemia-
mediated RAS stimulation. Furthermore, exercise results in the down-regulation of 
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components of the RAS system, such as ACE, ANG II, ANG II type 1 receptor 
(AT1), and NADPH oxidase (43, 57, 106, 121). Indeed, exercise has been shown to 
decrease plasma ANGII and local RAS activity in cardiac muscle, blood vessels and 
the brain (2, 121, 159). For example, Kar et al. (57) found that 3 weeks of treadmill 
running decreased ACE mRNA in the NTS, RVLM, PVN and decreased sympathetic 
outflow in rabbits with induced heart failure. Similarly, Pan et al. (102) found that 
non-T1DM Sprague-Dawley rats had decreased AT1 and NADPH oxidase protein 
expression and decreased superoxide production in the PVN following 3 to 4 weeks 
of exercise training. As aforementioned, the PVN is activated in T1DM through 
increased ANGII and decreased NO and this leads to sympathetic overactivity (103, 
161). Thus, inhibiting RAS activity and ANGII production, while increasing NO 
bioavailability, are likely mechanisms by which exercise reduces PVN mediated 
sympathetic outflow (102, 117). This influence of exercise on RAS activity in the 
PVN, NTS and RVLM makes it likely that exercise will also influence baroreflex 
function in T1DM (55, 57, 102). 
 Since exercise can influence both vascular and neural function, both must be 
taken into account when assessing the influence of exercise on BRS and baroreceptor 
set point (65, 120). Indeed, both the neural structures involved in the baroreflex arc 
and the carotid artery compliance can affect BRS and baroreceptor firing in diabetes 
and exercise (65, 94, 120). Monahan et al. (94) found that both age-related and 
exercise induced changes in the BRS corresponded to differences in carotid artery 
compliance in healthy men. However, Komine et al. (65) determined that endurance 
training increased BRS through alterations to the neural circuitry. In this vein, Miki et 
al. (88) reported that exercise has been demonstrated to cause a shift in baroreflex 
control of sympathetic nerve output to visceral organs. Further, Ruiz et al. (120) 
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reported that diabetic neuropathy is a more significant determinant of BRS than 
carotid artery elasticity in T2DM. Whether mediated by carotid artery compliance, 
neural circuitry or a combination of both, exercise has been shown to increase BRS 
after even a single bout of aerobic exercise in STZ-diabetic rats (55). Furthermore, the 
benefits of aerobic exercise on baroreflex function have been shown to persist after 3 
weeks of detraining subsequent to 10 weeks of moderate intensity training (50-70% 
maximal running speed) in STZ-diabetic rats (96). Thus, exercise can be an effective 
means to rescue or prevent baroreflex dysfunction and mitigate aberrations of CV 
function in T1DM (42, 65, 102). 
 Since baroreflex function is directly linked to the neural control of HR, 
fittingly, HRV is also influenced by exercise (119). In T1DM, there is generally a 
reduction in HRV; an indication of autonomic dysfunction (17). However, in 
individuals with T1DM there are inconsistent changes in HRV in response to 
exercise. Chen et al. (17) reported that children with T1DM with moderate to high 
physical activity did not differ in HRV compared to controls, whereas children with 
low physical activity had reduced HRV, suggesting only higher intensity exercise 
prevented a decline in HRV. On the other hand, Zoppini et al. (164) observed no 
change in total HRV following twice-weekly exercise over 6 months but did find that 
it increased HF power and lowered the LF/HF ratio, meaning there was a shift toward 
more parasympathetic output in the sympathovagal balance. Howorka et al. (49) 
tested HRV responses to 12 weeks of bicycle training in diabetic subjects who had 
differing levels of cardiovascular autonomic neuropathy. They found that patients 
without CAN had the greatest increases in HRV, patients with early CAN had lesser 
increases in HRV and patients with severe CAN did not improve following training; 
suggesting the level of neuropathy can dictate the outcomes of exercise (49). 
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Therefore, the intensity of exercise and stage of disease both factor in to the ability of 
exercise to modulate HRV in T1DM.  
Some inconsistency in the effectiveness of exercise modulation of HRV is 
reflected by the somewhat mixed outcomes for the influence of exercise on autonomic 
function in T1DM. For example, De Angelis et al. (5) found that exercise training in 
STZ-diabetic rats did not modify sympathetic tonus nor parasympathetic function. In 
the same model, Wegner et al. (153) reported that training did not induce changes in 
markers of parasympathetic innervation of the heart. However, vagal tonus and 
function have been observed to improve after acute and  prolonged training in the 
STZ-diabetic model (96, 111). Indeed,  the majority of literature supports the role of 
exercise as an effective means to improve and maintain autonomic function in 
diabetes (17, 150).  
 
1.7 Summary 
The pathogenesis of neuropathy in T1DM is a product of hyperglycemia-mediated 
AGEs, oxidative stress, metabolic dysfunction, inflammation and microangiopathy 
(41). Diabetic neuropathy affects peripheral and central aspects of the autonomic 
nervous system, alters the homeostatic maintenance of the sympathovagal balance and 
leads to a variety of systemic complications (30, 40). One of the most common and 
serious complications of DAN is cardiovascular dysregulation (85). The local RAS, 
PVN of the hypothalamus and baroreflex circuitry all interact to regulate autonomic 
cardiovascular control (40, 41). In T1DM, hyperglycemia causes an increase in local 
RAS, which in turn generates local ANGII mediated oxidative stress that can decrease 
insulin sensitivity, blunt the excitability of baroreceptor neurons and increase PVN 
activity (45, 72, 103, 148). This altered PVN activity interacts with the central 
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mediators of the baroreflex and directly with preganglionic neurons to influence 
sympathetic and parasympathetic outflow (8, 56). Thus, the baroreceptors, afferent 
nerves, central neural structures and efferent nerves of the baroreflex arc are all 
affected by T1DM (74). Together, dysfunction of these circuits underlie many of the 
serious functional CV complications associated with DAN (40, 100). Exercise is not 
only known to improve CV function directly but is also capable of improving ANS 
regulation of CV control in diabetics (17, 105, 150). Through improving insulin 
sensitivity and glucose metabolism, as well as the hormetic induction of antioxidant 
and anti-inflammatory factors, exercise is capable of decreasing local RAS, reducing 
PVN activity and improving the baroreflex and overall autonomic function in T1DM 
via both molecular and physiological mechanisms (36, 43, 65, 102, 159). Therefore, 
despite some inconsistencies between clinical and animal trials examining the 
effectiveness of exercise in the improvement of autonomic control of CV function, 
exercise remains an established, promising intervention for improving the prognosis 
of those with T1DM.  
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Figure 1.1. Protein glycation as the common cause of neuropathy; from Harati 
2007 (41). 
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Figure 1.2. The baroreflex circuit; from Guyenet 2006 (40). 
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CHAPTER 2 
2.1 Introduction 
One of the most common and serious complications of type 1 diabetes mellitus 
(T1DM) is diabetic autonomic neuropathy (DAN) (20, 95). The prevalence of DAN 
can range from roughly 10% in those recently diagnosed with T1DM, up to 90% in 
patients who are awaiting pancreas transplantation (20, 43, 95). Due to the breadth of 
the autonomic nervous system (ANS) throughout the body, DAN can influence the 
dysfunction of virtually any organ system  (95). The involvement of the ANS in the 
homeostasis of so many systems is likely implicated in the four-fold increase in 
mortality observed in T1DM patients with DAN (64). One of the most critical system 
affected by DAN is the cardiovascular (CV) system (57). Cardiovascular autonomic 
neuropathy (CAN) is a subset of DAN characterized by impaired autonomic control 
of the CV system (46). CAN is consistently associated with increased mortality. For 
instance, CAN has been reported to increase mortality of diabetics by a factor of 3.45 
and further, symptomatic CAN 5 years after the onset of type 2 diabetes has been 
shown to predict mortality 5 years later, even after adjusting for other cardiovascular 
disease risk factors (48, 57, 97).  
 The etiology of DAN and thus, CAN, stems from both metabolic and vascular 
pathologies that arise as consequences of sustained hyperglycemia (84, 100). 
Hyperglycemia leads to the irreversible binding of glucose to proteins, forming what 
are known as advanced glycation end-products (AGEs) (30). These AGEs exacerbate 
the formation of reactive oxygen species (ROS) by inhibiting the function of 
antioxidant enzymes and impair vascular dynamics by inhibiting nitric oxide synthase 
(NOS) function, promoting inflammation and atherosclerosis of endoneurial 
microvessels (30, 83, 89). This leads to further metabolic dysfunction, decreased 
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nerve conduction and reduced oxygen delivery to nerve tissue and ultimately, 
neuropathy (30, 81, 84). 
When this neuropathy occurs in the ANS it leads to an imbalance between the 
sympathetic (SNS) and parasympathetic (PSNS) nervous systems and dysregulates 
their control of cardiac and vascular dynamics (20, 97). Often, this balance shifts 
towards greater sympathetic activity in early T1DM as longer nerves are affected first 
and the longest efferent ANS nerve, the vagus nerve, facilitates 75% of all 
parasympathetic activity (20, 95). However, peripheral receptors, afferent nerves and 
central regions regulating autonomic activity are also implicated in the imbalance of 
the ANS during DAN (42, 50, 78). Together, the dysfunction of these ANS 
components leads to the sympathetic overactivity, hypertension, tachycardia and 
cardiac arrhythmias characteristic of  CAN in T1DM (21, 44, 46, 68, 80, 97). 
However, it has been observed that as the duration of T1DM progresses, so does 
neuropathy of the SNS, which can reduce sympathetic overactivity and its associated 
symptoms (46, 80). 
The most common methods for assessing CAN are heart rate variability 
(HRV) analysis and baroreflex sensitivity (BRS) measurement (5, 46, 52).  In T1DM, 
it has been shown that all aspects of the baroreflex arc can be impaired (51). For 
instance, both baroreceptor activity and excitability have been shown to be blunted  
(50, 78); the aortic depressor nerves have been observed to undergo axonal atrophy 
(78); central regions have been implicated  as the limiting factors of BRS (9, 27); and 
autonomic efferents, primarily of the PSNS, have been reported to have decreased 
tone, reduced responsiveness and decreased neurochemical activity in the heart (54, 
55). Each of these changes can act to reduce the sensitivity of the baroreflex 
independently and in conjunction. However, reduced HRV is often the earliest 
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symptom of CAN (80). Whether measured by time domain analysis or by frequency 
domain analysis and whether in clinical or experimental T1DM, HRV is consistently 
reported to be reduced in T1DM, with significant decreases observed as early as 10 
days after diabetes induction in the experimental streptozotocin (STZ) model of 
T1DM (34, 52, 79, 80, 102).  
Exercise has been demonstrated to be an effective means of improving these 
deficits of HRV and BRS in both clinical and experimental T1DM (11, 45, 61, 67). 
Such improvements have been attributed to improved insulin sensitivity, increased 
antioxidant and anti-inflammatory mediators and improved autonomic control of the 
CV system (23, 32, 96). However, despite clinical and experimental forms of T1DM 
demonstrating similar reductions of HRV and BRS in response to diabetes and 
improvement with exercise, there are marked differences in the initial changes to 
other CV parameters in their early stages (33). More specifically, in clinical T1DM, 
increases in heart rate (HR) and blood pressure (BP) are commonly reported  in early 
DAN (12, 14, 46, 47, 80, 95, 96). In contrast, experimental, STZ-induced T1DM is 
regularly associated with decreases in BP and HR beginning shortly after diabetes 
induction (16, 19, 34, 79, 91). Due to these opposing initial changes in BP and HR,  
exercise training is observed to effect contrasting outcomes on these CV parameters in 
experimental and clinical T1DM; namely, it results in an increase in BP and HR in 
experimental T1DM and a decrease in BP and HR in clinical T1DM (1, 31, 33, 53, 
67). As a result, both the increase and decrease of those CV factors are concurrently 
cited as exercise mediated improvements to CAN with little consideration of the fact 
that the changes are reversed between these types of diabetes (33). 
This may be due to a discrepancy between clinical and experimental T1DM in 
the disease progression. The most common method of STZ-diabetes induction is a 
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single bolus injection of STZ typically ranging from 50-100mg/kg (18, 74, 104). 
Aside from causing rapid pancreatic β-cell destruction and severe hyperglycemia, 
high doses of STZ have been associated with bone loss, increased lipid peroxidation, 
liver and kidney oxidative stress and even  immunosuppression (41, 62, 63, 69). 
However, increasingly, a multiple low-dose treatment of STZ is being demonstrated 
to more closely represent the gradual pathogenesis of clinical T1DM and has even 
been demonstrated to induce inflammation (74, 99). Indeed, Wei et al. (99) found that 
5 consecutive days of STZ injection at 25mg/Kg resulted in the generation of 
autoantibodies against insulin and islets of Langerhans and induced T cell infiltration 
in the β-cells of primates. Thus, this model may more closely replicate clinical 
parameters of the progression of DAN and CV dysfunction in T1DM by incorporating 
an immune response and more gradually introducing cytotoxicity and hyperglycemia 
(74, 96, 99). 
Another important difference between experimental and clinical T1DM is the 
common omission of insulin treatment in experimental diabetes. Indeed, of the 
experimental studies listed above that showed reductions in HR and BP, not one 
utilized insulin therapy and all animals presented severe hyperglycemia ranging from 
roughly 17-25mM (16, 19, 34, 79). As the severity and duration of hyperglycemia 
have been shown to influence the degree of diabetic neuropathy and with evidence 
that intensive insulin therapy can reduce neurologic complications of T1DM, it has 
been suggested that such acute and steep elevations of blood glucose levels in STZ-
induced diabetes are causing early-onset neuropathy to not only the PSNS but to the 
SNS and the sinoatrial node as well; which is likely mediating the observed reduction 
in BP and HR (2, 20, 30, 59, 64).  Indeed, intensive insulin therapy has been shown to 
restore BP and HR to control levels in STZ-diabetic rats (33, 35). Therefore, the 
44 
 
disparity of insulin therapy in clinical and experimental diabetes can have a 
significant impact on the progression of CAN and the CV dysfunction that is 
observed. However, even in clinical T1DM, it is often the case that chronic, moderate 
hyperglycemia is maintained  as a result of difficulties in regulating blood glucose in 
response to dynamic influences on glycemic control, such as food intake and exercise, 
combined with the tendency to err on the side of hyperglycemia in order circumvent 
the discomfort and danger associated with hypoglycemic episodes; which occur more 
frequently with DAN due to the impairment of the glucagon response (15, 70, 86, 94).  
Thus, whereas many diabetic complications and their modification by exercise 
training are similar between clinical and experimental diabetes, important 
inconsistencies exist that warrant resolution (2, 33). As such, the objectives of this 
study are to mirror the moderate hyperglycemic state common to poorly controlled 
human T1DM by employing a model of multiple low-dose STZ-induced diabetes in 
combination with insulin therapy, while examining the capacity of high intensity 
aerobic training to improve indices of CAN. Specifically, it is hypothesized that: a) 
this model of T1DM will prevent the decline in HR and BP typical of other STZ 
models, result in the hypertension and tachycardia typical of clinical T1DM and 
induce reductions in HRV and BRS; and b) exercise training will improve or prevent 
deficits in HRV and BRS.  
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2.2 Materials and Methods 
Ethics approval         
The protocols used in this investigation were approved by the Research Ethics Board of 
the University of Western Ontario (London, Ontario, Canada) and conformed to the 
guidelines of the Canadian Council on Animal Care (Appendix B.1). 
 
Animals          
Eight-week-old male Sprague-Dawley rats were obtained from Charles River 
Laboratories Canada (Saint-Constant, Quebec). The rats were housed in pairs and maintained 
on a 12-hour dark/light cycle at a constant temperature (20 ±1°C) and relative humidity 
(50%).  Rats were allowed access to standard rat chow and water ad libitum.  
 
Experimental groups         
Sixty-four rats were randomly assigned to one of four groups as follows: 1) Non-
diabetic sedentary control (C; n=16), 2) control exercise (CX; n=16), 3) diabetic sedentary 
control (D; n=16), 4) diabetic exercise (DX; n=16). A subset (n=8) of each group was used 
for tests of autonomic cardiovascular control at the end of the experiment. However, the total 
n used for testing varied based on animal availability at the time of the test. 
 
Experimental procedures 
Diabetes Induction 
Upon arrival rats were acclimatized to the laboratory setting for 5 days. T1DM 
was induced over 5 consecutive days by multiple intraperitoneal (IP) injections of 
20mg/kg streptozotocin (STZ; Sigma-Aldrich) dissolved in a citrate buffer (0.1 M, pH 
4.5). Diabetes was confirmed by blood glucose measurements greater than or equal 
to18mM on two consecutive days. If necessary, subsequent 20mg/kg STZ injections 
were administered until diabetes was confirmed (Appendix A1). Following the 
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confirmation of diabetes, insulin pellets (1 pellet; 2U insulin/day; Linplant, Linshin 
Canada, Inc., Toronto, Ontario, Canada) were implanted subcutaneously in the 
abdominal region. Insulin pellet dosages were then monitored for 1 week and adjusted 
(± 0.5 pellet) in order to obtain daily non-fasting blood glucose concentrations in the 
moderate hyperglycemic range of 9-15mM (Appendix A2). 
 
Exercise Protocol 
Prior to the initiation of the exercise training program, rodents were familiarized 
with the exercise equipment on two consecutive days. The familiarization consisted of 
two 15 minute sessions of running at progressive treadmill speeds up to 30 meters per 
minute. The exercise training program consisted of 1 hour of motor-driven treadmill 
training per day at 27 m/min with a 6 degree incline, 5 days per week, for 10 weeks. 
The exercise intensity was determined based on earlier research that investigated 
oxygen uptake in rats at various treadmill speeds. The chosen intensity was found to 
represent approximately 75-85% VO2max (90). 
 
Experimental measures 
Body Weight and Blood Glucose 
Body weights and non-fasting blood glucose concentrations were obtained 
weekly. Blood was obtained from the saphenous vein by venous puncture with a 30 
gauge needle and measured via Freestyle Lite Blood Glucose Monitoring System 
(Abbott Diabetes Care Inc., Mississauga, Ontario, Canada). 
 
Insulin Dose 
Insulin dose was determined by multiplying the total quantity of pellet implanted (0.5 
pellet increments) by the amount of insulin secreted per pellet (2 units of insulin/day/pellet) 
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divided by the body weight (Kg) of the rat.  Insulin pellet dosages were then monitored and 
adjusted throughout the course of the study in order to obtain daily non-fasting blood glucose 
concentrations in the moderate hyperglycemic range of 9-15 mM (Appendix A2). 
 
Intravenous Glucose Tolerance Test 
Intravenous glucose tolerance tests (IVGTT) were performed on all animals 
immediately prior to week 1 and at the end of week 10 of the exercise-training period. Rats 
were fasted for approximately 8 to 12 hours prior to the assay and did not perform exercise on 
the day of their IVGTT.  A sterile-filtered dextrose solution (50% dextrose, 50% ddH20) was 
injected (1g/kg) into the lateral tail vein of the conscious rat. Following dextrose infusion, 
blood glucose was measured at 5 minutes, 10 minutes and then at 10-minute intervals 
thereafter until blood glucose levels plateaued (Appendix A3).  
 
Non-invasive Blood Pressure 
 Non-invasive blood pressure (NIBP) recording was performed on all animals 
immediately prior to week 1 and at the end of week 10 of the exercise-training period. NIBP 
was recorded using the CODA non-invasive blood pressure system – tail cuff method (Kent 
Scientific Corp., Torrington, Connecticut, USA). Rats were restrained in the provided 
restraining tubes and tails were warmed with the included electrical heating pad. The 
occlusion cuff was fitted at the base of the tail while the volume-pressure recording (VPR) 
cuff was fitted 5cm distally. The occlusion pressure of the tail cuff was set to 180mmHg.  
Data were recorded using the bundled CODA acquisition system software in 3 sets of 5 
cycles. The first set consisted of 5 acclimation cycles, whereas sets 2 and 3 recorded 5 blood 
pressure measurements each.   
 
Surgery and Instrumentation 
To achieve a surgical plane of anesthesia, rats were placed in an induction chamber 
circulating 4% isoflurane (96% O2). Once motor reflexes were undetectable, rats were 
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transferred to a nosecone delivering 3% isoflurane (97% O2) and placed on a hot water pad 
(37°C). Immediately following transfer, rats were injected intraperitoneally (IP) with a 
25mg/Kg “cocktail” of urethane (16mg/mL) and α-chloralose (100mg/mL). A total of 10mL 
of urethane/α-chloralose was made, 5mL of which was diluted with 5mL of ddH2O and was 
used as needed to maintain anesthesia throughout data collection. Isoflurane anesthesia 
continued during instrumentation but was gradually removed near the end of surgery to gauge 
the depth of urethane/α-chloralose mediated anesthesia. 
Rats were cannulated with saline-infused polyethylene (PE90) catheters in the right 
jugular vein and carotid artery and each catheter was attached to a three-way stopcock. The 
jugular vein catheter was used for drug infusions and the carotid artery catheter was 
connected in series with a pressure transducer (PX272, Edwards Life Sciences, Irvine, 
California, USA) for arterial blood pressure measurements. Once cannulation was complete, 
rats were transported to a new location for data acquisition, a process that required roughly 
20-30 minutes. Heart rate (HR), systolic blood pressure (SBP) and mean arterial pressure 
(MAP) were determined from the blood pressure pulse waveform and were collected while 
the rats were under urethane/α-chloralose anesthesia in the supine position. The pressure 
transducer was calibrated using a standard analog manometer. Data were obtained using a 
PowerLab data acquisition system, digitized and recorded at1kHz using the bundled Lab 
Chart 7 Pro software (ADInstruments, Colorado Springs, Colorado, USA). 
 
Heart Rate Variability 
 Five minutes of resting, spontaneous BP and HR data were selected and analyzed for 
HRV parameters prior to drug infusions using the HRV module included with the Lab Chart 
software. Time domain analysis of the standard deviation between normal peak pulses of the 
pressure pulse waveform (SDNN) was quantified as a measure of the total variability of the 
HR. Frequency domain analysis of the high frequency (HF) band of the Fast Fourier 
Transform (FFT) of the data was assessed as an index of parasympathetically mediated HRV. 
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The ratio between low frequency (LF) and HF bands was measured to determine the 
contribution of sympathetic activity to the sympatho-vagally mediated LF HRV.  
 
Baroreflex Sensitivity 
 Baroreflex Sensitivity (BRS) was assessed using the modified Oxford technique (25, 
37). The slope of the linear regression line (see Figure 2.1) was taken for the linear portion of 
the systolic blood pressure-heart rate relationship (BPM mmHg-1) after rapid bolus injections 
of phenylephrine (PE) and sodium nitroprusside (SNP) dissolved in ddH2O. For each drug, 
the catheter was first filled with a 0.2mL volume to ensure the following dosage was accurate. 
After a stable baseline was obtained, a bolus injection of SNP (60ug/Kg, 110ug/mL) was 
rapidly infused (~5s) and the reflex SNS mediated tachycardia response was measured. The 
analysis began at the onset of SBP decrease after SNP infusion and ended when SBP reached 
its nadir. This was followed by a saline flush to washout any remaining SNP in the catheter. 
This same procedure was then followed using PE (12ug/Kg, 10ug/mL) to measure PSNS 
mediated reflex bradycardia, except that analysis began at the onset of SBP increase and 
ended when SBP reached its zenith (See Table 1). Exclusions of data points in the threshold 
and saturation regions of the sigmoid relationship were done manually in order to determine 
linear gain. Responses to PE and SNP were plotted separately and only regression lines 
(slopes) with correlation coefficients (r) ≥ 0.70 and p<0.05 were accepted (76, 85).  
 
Vascular Sympathetic Tone 
 To measure the sympathetic tone of the peripheral vasculature, a rapid bolus injection 
of the α-adrenergic receptor blocker, prazosin (85ug/Kg, 500ug/mL), was infused at the end 
of the baroreflex testing and the change in MAP was assessed. Following this protocol, 
animals were euthanized via exsanguination while still under urethane/α-chloralose 
anesthesia.  
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Data Analysis 
Body weight, blood glucose concentrations, NIBP and IVGTT data were compared 
using a two-way repeated measures analysis of variance (ANOVA) test, where the two factors 
were time (week) and specific treatment group (C, CX, D, DX). When significance was 
found, pairwise comparisons were made using the Fisher LSD post-hoc test. Endpoint 
measures were compared by one-way ANOVA between treatment groups. When significance 
was found, pairwise comparisons were made using the Fisher LSD post-hoc test. If initial 
statistical tests indicated significance, secondary analysis was performed using a two-way 
ANOVA to determine the main effects of and interaction between diabetes and exercise. If a 
significant interaction was found, pairwise comparisons were made using the Fisher LSD 
post-hoc test. 
The insulin dosages were compared using a one-tailed t-test. In the event that both the 
normality and equal variance assumptions were not met and significantly reduced the power 
of the parametric one-way ANOVA, a non-parametric Kruskal-Wallis one-way ANOVA on 
ranks was used and pairwise comparisons were made with a Dunn’s post-hoc test. 
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Figure 2.1. Example of a typical regression line used to calculate the slope of the systolic 
blood pressure-heart rate response to SNP for a single rat.   
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C CX D DX 
 SBP  HR SBP HR SBP HR SBP HR 
Zenith 
160.07 
 
288.17 
 
166.02 
 
297.27 
 
150.07 
 
311.11 
 
171.51 
 
268.72 
 
Baseline 
116.73 
 
357.83 
 
123.17 
 
340.32 
 
107.20 
 
354.66 
 
111.48 
 
333.15 
 
Nadir 
84.45 
 
407.00 
 
87.438 
 
379.50 
 
75.96 
 
398.97 
 
88.58 
 
360.87 
 
Table 2.1. Coincident average systolic blood pressure (SBP, mmHg) and heart rate (HR, 
BPM) at the baseline, zenith post-PE infusion and nadir post-SNP infusion. C, sedentary 
control, n=7; CX, control exercise, n=6; D, sedentary diabetic, n=8; DX, diabetic exercise, 
n=10. 
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2.3 Results 
Body Weight  
All groups (C, n=16; CX, n=16; D, n=15; DX, n=12) significantly gained 
weight over the course of the study (p<0.05). From Week 0 to Week 10, group C was 
significantly different from all other groups (p<0.05). From Week 1 to Week 10, 
group CX had significantly lower weight than C and significantly greater weight than 
D and DX (p<0.05), with the exception of group D at week 4. From Week 4 to Week 
10, with the exception of Week 6, group D had a significantly greater weight than DX 
(p<0.05). Overall, rats in the diabetic conditions were significantly lower weight than 
those in the non-diabetic conditions (p<0.001) and exercise conditions had 
significantly lower weight than their sedentary counterparts (p<0.001). However, 
there was not an interaction between diabetes and exercise on body weight (p=0.528) 
(Figure 2.1). 
 
Blood Glucose 
The C (n=16) and CX (n=15) groups did not change nor significantly differ in 
blood glucose throughout the study. The blood glucose of D (n=15) and DX (n=13) 
increased significantly following STZ treatment (p<0.05) and remained significantly 
elevated compared to C and CX throughout the study (p<0.05). Groups D and DX 
were significantly different from week 2 to week 6 and at week 9 (p<0.05). Rats in 
the diabetic conditions had significantly greater blood glucose concentrations than 
those in the non-diabetic conditions (p<0.001). However, there was not a significant 
interaction between diabetes and exercise on blood glucose (p=0.27) (Figure 2.2).  
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Intravenous Glucose Tolerance Test 
The glucose clearance rate (KG) of D (n=16) and DX (n=8) decreased from 
Week 1 to Week 10 (p<0.05) whereas the KG of CX (n=15) increased (p<0.05).  Both 
diabetic groups (D, DX) were significantly different from both control groups (C, 
n=16; CX) at Week 10 (p<0.05). Indeed, there was a significantly lower KG for rats in 
the diabetic conditions than for those in the non-diabetic conditions at Week 10 
(p<0.05). However, there was not a significant interaction between diabetes and 
exercise (p=0.906) (Figure 2.3).  
 
Insulin Dosages 
The amount of insulin supplementation that DX (n=18) received was 
significantly less than D (n=16) received at Week 10 (p<0.001) (Figure 2.4). 
 
Non-Invasive Blood Pressure 
 At week 1, the diabetic groups (D, =14; DX, n=11) had significantly higher 
BP than the control groups (C, n=15; CX, n=16) (p<0.05). All groups (C, CX, D, DX) 
increased in BP from week 1 to week 10 (p<0.05). At week 10, CX, D and DX had 
significantly greater BP than C (p<0.05). At week 1 there was significantly higher BP 
in rats in the diabetic conditions in comparison to those in the non-diabetic conditions 
(p<0.05), however, there was not a significant interaction between diabetes and 
exercise (p=0.076). Within non-diabetic groups at week 10, there was a significantly 
higher BP in the exercise than sedentary conditions (p<0.05). Within sedentary 
groups, there was significantly greater BP in the diabetic than non-diabetic conditions 
at week 10 (p<0.05). Indeed, there was a significant interaction between diabetes and 
exercise on BP at week 10 (p<0.05) (Figure 2.5).  
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 Heart Rate Variability and Heart Rate Variability 
Resting heart rate (BPM) under anesthesia was not significantly different 
between any groups (C, n=7; CX, n=7; D, n=8; DX, n=11) at week 10 (p=0.122) 
(Figure 2.6). Total HRV, as measured by the standard deviation of the normal pulse 
wave peaks (SDNN), was not significantly different between any groups (C, n=5; CX, 
n=7; D, n=8; DX, n=8) at Week 10 (p=0.369) (Figure 2.7). The parasympathetic, high 
frequency (HF) contribution to HRV had a significantly greater power for CX (n=7) 
and DX (n=8) in comparison to D (n=8) at Week 10 (p<0.05). Further, there was 
significantly greater HF HRV in exercise than sedentary conditions (p<0.05). 
However, there was not a significant interaction between diabetes and exercise on HF 
HRV (p=0.281) (Figure 2.8). The low frequency to high frequency (LF/HF) ratio, an 
index of sympathetically mediated HRV, was significantly greater in the D (n=7) 
group compared to all other groups (C, n=6; CX, n=6; DX, n=7) (p<0.05). The LF/HF 
ratio was significantly greater in the diabetic than non-diabetic conditions and in the 
sedentary than exercise conditions (p<0.05), however, there was not a significant 
interaction between diabetes and exercise (p=0.068) (Figure 2.9).  
 
Vascular Sympathetic Tone 
The decrease in MAP in response to prazosin infusion was significantly 
greater in the D (n=5) group compared to all other groups (C, n=8; CX, n=7; DX, 
n=7) (p<0.05). Within the diabetic groups (D, DX), there was a significantly greater 
decrease in MAP in the sedentary condition compared to the exercise condition 
(p<0.05). There was a significant interaction between diabetes and exercise (p<0.05). 
Within the sedentary groups (C, D), there was a significantly greater decrease in MAP 
in the diabetic than non-diabetic condition (p<0.05) (Figure 2.10).  
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Baroreflex Sensitivity 
The slope of the tachycardia response to sodium nitroprusside infusion was 
not significantly different between any groups (C, n=7; CX, n=6; D, n=6; DX, n=10) 
(p=0.86) (Figure 2.11). The slope of the bradycardia response to phenylephrine was 
significantly greater in the C (n=7) and DX (n=10) groups compared to the D (n=7) 
group (p<0.05) but not CX (n=5). Within diabetic groups, there was a significantly 
greater bradycardia response in the exercise than sedentary group (p<0.05). There was 
a significant interaction between diabetes and exercise on the slope of the bradycardia 
response (p<0.05) (Figure 2.12).  
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Figure 2.2. Weekly body weights.  Data are mean ± SE. C, sedentary control (n=16);  CX, 
control exercise (n=16); D, sedentary diabetic (n=15); DX, diabetic exercise (n=12). * = 
significantly different from C (p<0.05). # = significantly different from CX (p<0.05). Ω = 
significantly different from D (p<0.05). There is a statistically significant difference between 
diabetic and non-diabetic conditions (p<0.001). There is a statistically significant difference 
between exercise and sedentary conditions (p<0.05).  
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Figure 2.3. Weekly blood glucose concentrations.  Data are mean ± SE. C, sedentary control 
(n=16); CX, control exercise (n=15); D, sedentary diabetic (n=15); DX, diabetic exercise 
(n=13). * = significantly different from C (p<0.05). # = significantly different from CX 
(p<0.05). There is a significant difference between diabetic and non-diabetic conditions 
(p<0.001).  
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Figure 2.4. IVGTT glucose clearance (KG) values at week 1 and week 10.  Data are mean 
± SE. C, sedentary control (n=16); CX, control exercise (n=15); D, sedentary diabetic 
(n=16); DX, diabetic exercise (n=8). * = significantly different from C (p<0.05). # = 
significantly different from CX (p<0.05). $ = significantly different from Week 1 
(p<0.05). There is a statistically significant difference between diabetic and non-diabetic 
conditions at week 10 (p<0.001). 
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Figure 2.5. Insulin dosages at Week 10.  Data are mean ± SE. D, sedentary diabetic 
(n=16); DX, diabetic exercise (n=18). Ω = significantly different from D (p<0.001).  
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Figure 2.6. NIBP values at week 1 and week 10.  Data are mean ± SE. C, sedentary 
control (n=15); CX, control exercise (n=16); D, sedentary diabetic (n=14); DX, diabetic 
exercise (n=11). * = significantly different from C (p<0.05). # = significantly different 
from CX (p<0.05). $ = significantly different from Week 1 (p<0.05). There is a 
statistically significant interaction between diabetes and exercise at week 10 (p<0.05). 
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Figure 2.7. Heart Rate (beats per minute) at Week 10.  Data are mean ± SE. C, sedentary 
control (n=7); CX, control exercise (n=7); D, sedentary diabetic (n=8); DX, diabetic 
exercise (n=11). There is not a statistically significant difference between groups (p=0.122).  
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Figure 2.8. Total HRV (SDNN) at Week 10.  Data are mean ± SE. C, sedentary control 
(n=5); CX, control exercise (n=7); D, sedentary diabetic (n=8); DX, diabetic exercise 
(n=8). There is not a statistically significant difference between groups (p=0.369).  
 
0
5
10
15
20
25
D DX CX C 
SD
N
N
 (m
s)
 
64 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. High Frequency (parasympathetic) HRV component at Week 10.  Data are mean 
± SE. C, sedentary control (n=6); CX, control exercise (n=7); D, sedentary diabetic (n=8); 
DX, diabetic exercise (n=8). Ω = significantly different from D (p<0.05). There was a 
statistically significant difference between exercise and sedentary conditions (p<0.05). 
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Figure 2.10. Low frequency to high frequency ratio (sympathetic) HRV component at Week 
10.  Data are mean ± SE. C, sedentary control (n=6); CX, control exercise (n=6); D, 
sedentary diabetic (n=7); DX, diabetic exercise (n=7). * = significantly different from C 
(p<0.05). # = significantly different from CX (p<0.05). @ = significantly different from DX 
(p<0.05). There was a statistically significant difference between diabetic and non-diabetic 
and exercise and sedentary conditions (p<0.05). 
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Figure 2.11. Vascular sympathetic tone at week 10. This was determined by measuring the 
percent change in MAP after prazosin treatment at Week 10.  Data are mean ± SE. C, 
sedentary control (n=8); CX, control exercise (n=7); D, sedentary diabetic (n=5); DX, 
diabetic exercise (n=7). * = significantly different from C (p<0.05). # = significantly 
different from CX (p<0.05). @ = significantly different from DX (p<0.05). There was a 
statistically significant interaction between diabetes and exercise (p<0.05).  
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Figure 2.12. Tachycardia baroreflex response sensitivity to sodium nitroprusside 
at Week 10.  Data are mean ± SE. C, sedentary control (n=7); CX, control 
exercise (n=6); D, sedentary diabetic (n=6); DX, diabetic exercise (n=10). There 
is not a statistically significant difference between groups (p=0.86). 
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Figure 2.13. Bradycardia baroreflex response to phenylephrine at Week 10.  Data 
are mean ± SE. C, sedentary control (n=7); CX, control exercise (n=5); D, sedentary 
diabetic (n=7); DX, diabetic exercise (n=10). Ω = significantly different from D 
(p<0.05). There was a statistically significant interaction between diabetes and 
exercise (p<0.05). 
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2.4 Discussion 
This study demonstrated that a multiple low-dose STZ model with moderate 
hyperglycemia, maintained using insulin therapy, produced deficits in cardiovascular 
autonomic function without inducing the resting bradycardia or hypotension typical of 
other STZ models. Furthermore, this study showed that exercise training can prevent 
the alteration of cardiovascular autonomic function caused by diabetes in this model.  
Although time domain analysis of total HRV, as measured by the SDNN, did 
not demonstrate differences between groups, frequency domain analysis of the 
distinct contributions of the autonomic branches to HRV did reveal significant 
differences. For instance, there was a significant difference in the HF power between 
the D group and both exercise groups. Furthermore, the LF/HF ratio was significantly 
higher in the D group compared to all other groups. Since the HF power corresponds 
to the level of vagally-mediated (parasympathetic) HRV and the LF/HF ratio is a 
measure of sympathovagal balance, these results indicate that there was significantly 
lower parasympathetically-mediated HRV in the D group compared to the exercise 
groups as well as an overall shift toward greater sympathetic activity in the 
sympathovagal balance of the D group (75, 103). Thus, exercise training prevented 
the dysregulation of the sympathovagal balance caused by diabetes. These findings 
are similar to those of other experiments of both clinical and experimental diabetes. A 
study by Zoppini et al. (103) demonstrated an increase in HF power and a decrease in 
the LF/HF ratio but no change in total HRV, after 6 months of exercise in T2DM 
patients. Mostarda et al. (61) found that STZ-induced diabetes reduced the HF 
component of HRV which was improved by exercise. Also comparable to the present 
study, they found that the vagal tonus of the control exercised rats did not differ from 
sedentary controls (61). Chen et al. (11) reported that children with type 1 diabetes 
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who performed high physical activity did not differ from controls in HRV; however, 
they did find that children with type 1 diabetes who had low physical activity had 
significantly reduced HRV compared to both active T1DM and control children. 
Indeed, most studies report that diabetes decreases HRV even from control levels, yet 
it is important to note that the timing of HRV decline is variable (2). Schaan et al. (79) 
measured HRV at 5-7, 14, 30, 45 and 90 days post-STZ-induction of diabetes in rats 
and found that there were no significant differences from control in HRV until the 30 
or 45 day time points. Moreover, in this STZ model no insulin therapy was used, 
which could indicate that significant decreases in HRV in the present study would 
have taken even longer due to the reduced hyperglycemic insult. Indeed, the authors 
reported that there was a negative correlation between plasma glucose levels and 
reductions in HRV (79); an observation also noted by Chen et al. (10) in a study of 
children with T1DM, in which they found that glycemic control had a greater negative 
correlation with HRV than did disease duration. However, regardless of severity or 
duration of hyperglycemia, it has been demonstrated that exercise is an effective 
means to improve HRV as long as pre-existing CAN is not too severe (36, 75).  
In fact, the current study provides evidence that the ability of exercise to 
ameliorate cardiovascular autonomic dysfunction may be independent from its ability 
to reduce blood glucose, which contradicts such an inference suggested by previous 
studies (13, 87, 98). The IVGTT performed at the end of the 10 week exercise period 
demonstrated an increased glucose clearance (KG) in the CX group compared to week 
1 of training, which indicates there was an increase in glucose tolerance in the 
exercise control group. In both diabetic groups there was a decrease in KG to nearly 
the same level that was significantly different from their week 1 values and the week 
10 values of the C and CX groups. While this would normally indicate that both of the 
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diabetic groups had equally impaired glucose tolerance, it was also the case that the 
DX group received approximately half of the dosage of exogenous insulin than the D 
group received. If this entails that the area under the curve for insulin over a given 
time during IVGTT would have been greater in the diabetic group, then with the KG 
being equal, this would indicate there was a greater insulin sensitivity in the diabetic 
exercise group (29, 92). Together, these IVGTT results indicate improved glucose 
metabolism and insulin sensitivity as a result of exercise training (87). However, since 
the BG concentration in this study was held in a relatively constant range, any 
exercise-induced improvements of CV function that resulted from improved glucose 
metabolism would not have been mediated through an insulin sensitivity-induced 
reduction in systemic blood glucose but could still be the result of tissue-specific 
improvements in glucose utilization (6, 66). This should be borne in mind when 
considering the effects of diabetes and exercise on BRS.  
The sensitivity or “gain” of baroreflex-mediated tachycardia and bradycardia 
were examined in this study by measuring the slope of the regression line of the 
ΔHR/ΔSBP in response to the vasodilator SNP and the vasoconstrictor PE, 
respectively. The slope of the tachycardia response was not significantly different 
between any of the groups. The slope of the bradycardia response was not 
significantly different from C in either exercise group; nor was there a significant 
difference between the exercise groups. However, the slope of the bradycardia 
response in the D group was significantly reduced compared to the C and DX groups. 
The tachycardia elicited by SNP is mediated by baroreflex-induced disinhibition of 
the RVLM, resulting in sympathoexcitation (28, 72). Thus, neither diabetes nor 
exercise affected the function of the sympathetic arm of the baroreflex. Conversely, 
the bradycardia induced by PE is mediated by baroreflex-induced inhibition of the 
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RVLM, resulting in depressed sympathetic activity and increased parasympathetic 
activity (28, 72). Therefore, diabetes reduced the function of the parasympathetic arm 
of the baroreflex, a decline which was prevented by exercise. These results are 
directly in line with a study by Jorge et al. (40) that investigated BRS after 30 days of 
STZ-diabetes, with and without aerobic exercise during the final 5 days. They found 
that neither diabetes nor exercise had any effect on the tachycardia reflex to SNP. 
Further, they found that control exercised rats did not differ from the control group 
before or after exercise training in either response. However, similar to the current 
study, they found that diabetes decreased the bradycardia response to PE and that this 
decrease was ameliorated by exercise (40). This indicates that the acute effect of 
exercise in a more severe, yet shorter duration, model were similar to the outcomes of 
the model employed in this experiment, giving credence to the postulation that the 
multiple low-dose STZ, insulin supplementation approach reduces the speed of 
neuropathic progression. However, it should be noted that Maeda et al. (55) observed 
a decreased tachycardia response and unchanged bradycardia response after only 5 
days post-STZ treatment. This suggested that in the very short-term, there may be 
some neural toxicity of STZ directly on the SNS (24, 82).  
An explanation of why short-term exercise in the study by Jorge et al. (40) 
appears to have been as effective as endurance training in the current study may be 
explained by the findings of Bernardi et al. (3), who elucidated the importance of 
tissue oxygenation in T1DM. They demonstrated that blunted  parasympathetic BRS 
in T1DM patients was improved by both oxygen supplementation and deep breathing 
to the same degree, which implicated the increased respiration and oxygen delivery 
resultant of exercise could have been mediating increases in BRS (3). This led the 
authors to suggest hypoxia in T1DM functionally restrains parasympathetic activity 
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(3). Most of the studies discussed thus far, including this current experiment, are all in 
line with the observation that parasympathetic dysfunction precedes sympathetic 
dysfunction (38). However, reduced BRS can be attributed to defects in the 
baroreceptors, baroreceptor afferent nerves, CNS structures or efferent fibres of the 
baroreflex circuit (40, 51, 78). The observation in the present study that the 
tachycardia response of the baroreflex was unimpaired by diabetes, while the 
bradycardia response was, suggests that the afferent arm and central regulators of the 
baroreflex were not dysfunctioning and that the observed decrement of baroreflex 
bradycardia was due to efferent parasympathetic neuropathy (16, 78). Since the 
maintenance of the tachycardia response to SNP indicates the functionality of the 
baroreceptors in response to stretch was unhindered, it can also be inferred that 
arterial stiffening was not a likely cause for the decreased bradycardia response (77). 
It has been reported that arterial stiffening results in reduced arterial compliance, 
which limits the magnitude of arterial stretch and thereby, the magnitude of the 
baroreceptor firing (58). In fact, arterial stiffness has even been associated with 
decreased HRV in type 1 diabetics (39). However, Ruiz et al. (77) reported that 
neuropathy is a greater determinant of BRS than carotid artery elasticity in diabetes. 
Further, Komine et al. (45) demonstrated the effects of exercise on BRS are mediated 
through neural alterations, as opposed to changes in vessel wall compliance of the 
carotid artery. Thus, the alteration in BRS of the bradycardia response in this study 
was most likely due to the dysfunction of parasympathetic efferents, which was 
prevented via exercise. This is corroborated by the VST observed in this study, which 
was measured through the changes in MAP in response to prazosin treatment.   
Prazosin injection resulted in a decrease in MAP in all groups. This decrease 
in MAP, relative to baseline, was not significantly different between the C, CX and 
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DX groups. Conversely, the drop in MAP from baseline in the D group was 
significant compared to all other groups; the reduction being approximately twice as 
large. Prazosin is an α1-adrenergic receptor antagonist that blocks the sympathetic 
contribution to peripheral resistance at the level of the vascular smooth muscle (56, 
71). Thus, a larger reduction in blood pressure in response to prazosin treatment 
indicates a greater sympathetic tone in the maintenance of the baseline MAP (17, 73). 
Therefore, the significantly greater decrease in the MAP of the D group in this study 
indicates that diabetes resulted in a significant elevation of vascular sympathetic tone, 
which was prevented by exercise training. Martinez-Nieves and Dunbar (56) reported 
a similar finding that male diabetic rats had a greater decrease in MAP after a bolus 
injection of prazosin compared to their control cohorts. They postulated that an 
elevated prazosin response could be the result of increased α1-adrenergic receptor 
sensitivity (56). However, the finding that treatment with PE, an α1-adrenergic 
receptor agonist, did not have a greater impact in the diabetic group makes this an 
unlikely explanation in this experiment (26). The result of prazosin treatment is in 
concordance with both the HRV and BRS results in this study. HRV demonstrated a 
similar shift toward sympathetic activity in the sympathovagal balance, as determined 
by the LF/HF ratio. The BRS tests demonstrated a significant reduction in 
parasympathetic modulation of the HR. In conjunction, these findings point toward a 
diabetes-induced reduction in parasympathetic function, the consequent loss of PSNS-
mediated sympathetic inhibition and resultant sympathetic overactivity (95, 97). This 
may explain the outcome of the NIBP measurement in this study. 
The NIBP measurement of MAP in conscious rats showed a significant 
increase in blood pressure at week 10 compared to week 1in all groups. At week 1, 
the D and DX groups both had higher BP than the C and CX groups. At week 10, D, 
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DX and CX all had similarly elevated blood pressures compared to C. The elevation 
of BP in the diabetic groups at week 1 was likely resultant of their recent, acute 
elevation in BG in response to STZ treatment, as acute elevations in BG have been 
shown to increase BP in both normal and type 1 diabetic individuals, as well as 
animals (4, 8, 22, 49). It is also possible that BP was elevated due to the osmotic 
pressure caused by hyperglycemia; however, pre-treatment with the free radical 
scavenger, glutathione, has been shown to prevent any acute hemodynamic changes 
associated with hyperglycemia, suggesting its effects are more likely mediated by the 
impairment of endothelial-derived relaxing factors, such as NO (22, 65). Also, stress 
could have played a role in elevating the BPs of the diabetic groups at week 1. 
Restraint alone has been observed to dramatically increase heat shock protein 
expression in both the adrenal cortex and the vasculature (93). In fact, the stress of 
training is probably why both exercise groups had BP values similar to the D group at 
week 10. Moraska et al. (60) showed that 8 weeks of forced treadmill training caused 
adrenal hypertrophy, decreased corticosterone-binding globulin, suppressed 
lymphocyte proliferation and other factors indicative of chronic stress. Likewise, 
Brown et al. (7) reported elevated heat shock proteins, serum corticosterone and 
decreased spleen weights after up to 10 days of treadmill training. Forced treadmill 
exercise has also been demonstrated to mediate increases in BP and HR that exceed 
the values of voluntary wheel running rats, which is indicative of a stress response 
(60, 101). This is particularly relevant in the present study as the NIBP measurements 
were taken during the week. Therefore, both the chronic stress of long-term training 
and acute effects of forced training could have contributed to elevated BP in the 
exercise groups. The D group, however, demonstrated increased BP without exposure 
to acute or chronic training stress, suggesting their BP values were most likely the 
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result of chronic diabetes. As a result of the previous findings that indicated 
sympathetic overactivity in the D group and the strong association between 
sympathetic tone and BP, it is plausible that the observed hypertension is driven by 
sympathetic overactivity in this model (73). However, urine albumin excretion was 
not measured in this study, so it is not possible to rule out that diabetic nephropathy 
contributed to the increased BP (88). Unfortunately, HR extrapolations from the NIBP 
recordings were sporadic and deemed unreliable. However, while at rest under 
urethane/α-chloralose anesthesia, there was no significant difference between any of 
the groups in HR. Although it is unknown if non-invasive recording would have 
demonstrated diabetes-induced tachycardia, this observation still demonstrates that 
the commonly reported decrease in HR in STZ diabetes was prevented in the present 
model (91).   
 
2.5 Conclusion 
Cardiovascular autonomic neuropathy is a common form of autonomic 
dysfunction in T1DM that is highly associated with mortality (80). HRV and BRS are 
common indices of CAN that have been observed to improve with exercise training, 
highlighting why exercise is such an important nonpharmcological intervention in the 
prevention of T1DM complications. However, experimental models of T1DM often 
demonstrate fundamental differences from clinical T1DM in the nature and 
progression of alterations to CV parameters in response to diabetes and exercise (33, 
51). The objective of this study was to explore the potential of a multiple low-dose 
STZ model of T1DM, paired with insulin therapy to maintain moderate 
hyperglycemia, as a means to more closely represent the conditions of human T1DM.  
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 In this study it was found that the only measures that differed from C in the 
CX group were the IVGTT and NIBP. Thus, training did result in metabolic 
improvements, as indicated by increased glucose tolerance; however, exercise did not 
appear to elicit any advantages in HRV, BRS or BP over the non-diabetic sedentary 
state. This suggests that the chronic stress of forced treadmill training may have 
prevented many of the benefits normally conferred by exercise to the CX group (7, 
60, 101). In the D group, a blunted baroreflex bradycardia response, a shift in LF/HF 
toward sympathetic activity and a significant drop in BP in response to prazosin 
compared to C indicated diabetes-induced parasympathetic withdrawal and 
sympathetic overactivity (28, 75, 103). This was supported by the significantly higher 
NIBP compared to C. Similarly to CX, the only differences between DX and C in this 
study were in IVGTT and NIBP. However, unlike CX, this implies that exercise 
training resulted in significant adaptations. Indeed, exercise training in the DX group 
was able to prevent many of the defects listed above that occurred in the D group as a 
result of diabetes. Specifically, exercise prevented the sympathovagal imbalance in 
the modulation of HRV, prevented the overactivity of the vascular sympathetic tone 
and maintained the sensitivity of the parasympathetically-mediated baroreflex 
bradycardia. Therefore, the present study demonstrated that STZ models of T1DM 
can be augmented to more accurately reflect clinical T1DM by implementing 
progressive induction and insulin treatment. Further, this study reinforces the 
importance and effectiveness of exercise as a means to prevent the progression of 
cardiovascular autonomic neuropathy. 
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APPENDIX A 
A1. Streptozotocin Induction Protocol (Rat) 
 
REVISION DATE: JUNE 13, 2012 
 
PURPOSE: 
To induce Type I diabetes in rats 
 
MATERIALS: 
Gloves 
Lab Coat 
Streptozotocin (STZ) 
5X Stock Citric Acid/Citrate Buffer  
- Anhydrous Citric Acid 
- Sodium Citrate Dihydrate 
- MilliQ Deionized Water 
13M HCl 
3 Falcon Tube 
Sterile Filter 
 
EQUIPMENT: 
Biological Safety Cabinet 
Weigh Scale 
pH Meter 
 
PROCEDURE: 
Preparing 5X Citric Acid/Citrate Buffer 
1. For a pH 4.6 buffer at 765 mM (5X stock solution), in a beaker, Add 
i. 13.8g Anhydrous Citric Acid (Sigma) or 15.1g Citric Acid 
Monohydrate 
ii. 23.8g Sodium Citrate Dihydrate (Sigma) 
Mix into    iii.   175mL of MilliQ water 
The pH should be at 4.6, Add HCl or NaOH to adjust (do not over-shoot pH) 
2. Once the proper pH is obtained, add MilliQ water until you are close to the 200 ml 
mark (pH will move slightly).  If satisfied with the pH, adjust volume in a 250 ml 
graduated cylinder and filter in a 0.2µm filter. 
 
3. Store at room temperature.  This is your 5X stock solution. 
 
Making up Streptozotocin (STZ) for Injection 
**NOTE Animals should be pre-weighed prior to making up STZ to ensure 
accurate amounts of STZ to be prepared. 
 
1. Using pre-made buffer, put 1 mL of buffer in a 50 mL Falcon Tube and add 4 mL 
of distilled water filtered through a 0.2µm syringe filter.  Check the pH.  This 
gives you a working concentration of 153 mM 
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2. The desired pH is between 4.5-4.7.  Under the fume hood, add 1 drop at a time of 
concentrated HCl to the buffer, checking pH in between until desired pH is 
reached.     
 
3. Once pH is reached, add 1 mL distilled water (sterile filtered through a 0.2µm 
syringe filter as before).  If pH is below 4.5, restart. 
 
4. Weigh out an appropriate amount of STZ for the number of animals (see 
calculations below) that will be injected in a 15 minute time frame. 
 
 
Ex. Rats will be injected at 20mg/kg, so for 10 animals at an ideal weight of 200g 
(avg. weight of rats to be injected), you will require a minimum of 40mg.  
  20mg/kg X 0.2kg = 4mg per animal 
The amount of STZ weighed out should be more than the minimum as some 
solution will be lost in filtering. (4mg (per animal) X 12 rats = 48mg total 
(0.048g) 
5. Dissolve the STZ into buffer (keeping in mind a comfortable injection volume).  
Shake to dissolve powder (approx. 1min).  Sterile filter using a 0.2µm syringe 
filter.   
Ex. 48mg STZ ÷ 3 mL buffer = 16mg/mL solution 
 4mg ÷ 16mg/mL solution = 0.25mL 
6. STZ is time dependent and must be used within 15 minutes 
 
Injecting and Follow-Up of the Animals 
1. Promptly inject each rat with the solution (intraperitoneal) at a dosage rate of 
20mg/mL (in this example, 0.25mL).  Do not use anymore STZ solution more 
than 15 minutes after it has been dissolved in the sodium citrate buffer. 
 
2. Dispose of any container having come into contact with the STZ (in either powder 
or dissolved form) into a biohazardous waste receptacle.  Dispose of needles into a 
sharps container. 
 
3. Return injected rats to their cage.  Record the date of STZ injection and add a 
biohazard label to the cage (leave biohazard label on cage for at least 3 days 
following the last injection). 
 
4. Repeat this procedure the following day. 
 
5. Check blood glucose daily.  Diabetes is achieved with two non-fasting blood 
glucose readings of >18 mmol  Diabetes should be achieved after 5-8 injections 
(i.p. 20mg/kg). 
 
Reference: 
Low dose STZ induction protocol. Animal Models of Diabetic Complications 
Consortium AMDCC Protocols.2003 
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A2. Insulin Pellet Implantation Protocol 
 
MATERIALS: 
LinShin LinPlant Insulin Pellet 
Rat anesthetic - Isoflurane 
Ampicillin 
Sterile water 
1ml syringe with 25 g needle 
10% providone-iodine solution 
gauze (or swab) 
Tissue forceps 
Scalpel handle and blades (or scissors) 
Silk suture 
Needle drivers 
 
EQUIPMENT: 
IsofluoraneAnaesthetic Machine 
Hair clippers 
Heat lamp 
 
Special Safety: 
 
Must don lab coat and gloves before handling rodents.  Any bite or scratch that breaks 
the skin must be thoroughly scrubbed with soap and water (report to Occupational 
Health and Safety). 
 
Procedure: 
 
Pellet implantation (for a rat): 
 
1. Anesthetize the animal using the isofluorane machine by placing it in the 
induction chamber. Set isoflurane to 4-5% with an O2 flow rate of 1L/min. Open 
the stopcock valve so gas reaches the chamber.  Keep in chamber until the animal 
is unconscious. 
 
2. Remove the animal and place its nose in the nose cone, reduce the isofluorane to 
3% to maintain the plane of anesthesia.   
 
3. Shave the area where the pellet is to be implanted.  
 
4. Using gauze (or a swab), apply 10% providone-iodine solution to the skin, 
followed by 70% ethanol, to disinfect the site of insertion. 
 
5. Hold the skin with forceps and make a subcutaneous incision. 
 
6. Cleanse a 12g trocar with 10% providone-iodine solution and insert it through the 
puncture site to a depth of at least 2 cm. 
 
7. Using forceps, briefly immerse the pellet in 10% providone-iodine solution, rinse 
with saline and insert into the subcutaneous region.  
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8. Use 1 pellet for the first 350g of body weight.  
 
9. Pinch the skin closed after the last pellet is inserted. Place a drop of 10 % 
providone-iodine solution over the opening.  
 
10. Close the incision by suturing. 
 
11. Place the animal under a heat lamp and monitor until it recovers from anesthesia. 
 
12. Record on the cage card that insulin pellets have been implanted.  
 
 
Pellet removal: 
1. Anesthetize the animal as described above for implantation.  
 
2. Shave and palpate the area of implantation to locate pellets. Sterilize this area by 
applying 10% providone-iodine solution followed by 70% ethanol. 
 
3. Using a scalpel (or scissors), make an incision through the skin superficial to the 
location of the pellets.  
 
4. Using forceps, remove the pellet. Some connective tissue may need to be cut away 
using scissors. Discard the pellet. 
 
5. Close the incision by suturing.  
 
6. Place the animal under a heat lamp and monitor until it recovers from anesthesia. 
 
7. Record on the cage card that the pellets have been removed. 
 
 
References: 
http://www.linshincanada.com 
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A3. Intravenous Glucose Tolerance Test Protocol (Rat) 
 
MATERIALS: 
15 ml Falcon tube  
D-glucose 
Distilled water 
0.2 um syringe filter 
5 ml vacutainer 
Lidocaine Cream 
3 ml syringe  
Restraining towel 
Microcentrifuge tubes 
Vaseline 
27 G needles 
30 G needles 
Gauze squares 
 
EQUIPMENT: 
Mettler balance 
Biological safety cabinet 
Heat lamp with 175 watt bulb 
Glucometer (Freestyle mini) 
Timer 
 
 
Special Safety: 
 
Must don lab coat and gloves before handling rats.  Any bite or scratch that breaks the 
skin must be thoroughly scrubbed with soap and water (report to Occupational Health 
and Safety). 
 
 
PROCEDURE: 
 
Fasting Rats: 
 
1. Fast animals for 8-12 hours prior to the tolerance test 
 
Glucose preparation: 
 
1. On the morning of the IVGTT, dispense 5ml distilled water into a clean 15 ml 
Falcon tube. 
 
2. Weigh out 5 grams of D-glucose, and add it to the tube containing the sterile 
water. Dissolve by vortexing to result in a 50% glucose solution. 
 
3. In a biological safety cabinet, sterilize the glucose solution using a 0.2 um syringe 
filter. 
 
4. Transfer the sterile glucose solution to a new sterile 15mL Falcon tube. 
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Intravenous Glucose Tolerance Test (IVGTT): 
1. Place the cage containing the rat under a heat lamp. Remove the tube from the 
cage, and provide water for the rat. Warm the rat in this manner for 10 minutes. 
 
2. Remove the rat from the cage and scrub the tail using soap and water. 
 
3. Measure and record the rat’s weight. 
 
4. Obtain a baseline blood glucose reading from saphenous vein and collect a 
baseline serum sample (keep blood sample on ice). 
 
5. Return the rat to the cage and warm for an additional 20 minutes. 
 
6. Place the rat’s tail in a container of warm tap water for 30-60 seconds. 
 
7. One person should dry the tail and restrain the rat by wrapping it in a green drape 
so the tail is exposed. Occlude the lateral tail vein by applying pressure.  
 
8. Using a 3 ml syringe and a 27 G needle, a second person will draw up the 50% 
glucose solution at a dose of 1g/kg (2 ml/kg). Locate the lateral tail vein and draw 
back on the plunger to ensure that the needle is within the vein.  
 
9. Release the occlusion while the glucose solution is injected. Draw back the 
plunger a couple of times during the injection to ensure that the needle remains 
located within the vein. 
 
10. Start the timer and return the rat to its cage. Continue warming it for the duration 
of the IVGTT. 
 
11. Check and record the blood glucose values for the rat at 5, 10, 20, 30, 40, 50 and 
60 minutes post glucose challenge. If by 60 minutes, the blood glucose value 
hasn’t returned to baseline, continue to check every 30 minutes until it does so (up 
to a maximum of 180 minutes). 
 
12. Obtain a blood serum sample 10 minutes following D-glucose injection (store at 
-70°C until insulin analyses). 
 
13. Upon completion of the IVGTT, remove the rat from under the heat lamp and 
return the tube to the cage. Place food on the wire lid of the cage, and ensure that 
the rat has access to water. 
 
14. Note on the cage card that an IVGTT has been performed. 
 
Reference: 
Straczkowski M et al, The effect of exercise training on glucose tolerance and skeletal 
muscle triacylglycerol in rats fed with a high-fat diet. Diabetes and Metabolism 
(2001) 21 p19. 
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